Drug Profile
NN 9423
Alternative Names: NN9423; NNC 92041706; NNC 92041706 A; Tri-agonist 1706Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 30 Jun 2020 Discontinued - Phase-I for Obesity in USA (SC) due to prioritisation within the obesity care development portfolio
- 28 Apr 2020 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)
- 31 Aug 2017 Novo Nordisk completes a phase I trial in Obesity in USA (SC) (NCT03095807)